Japan’s regulators approved the world’s first therapy derived from induced pluripotent stem cells (iPSCs) to treat Parkinson’s disease, marking a regulatory milestone for regenerative medicine. The decision follows years of academic and clinical development in Japan’s iPSC ecosystem and establishes a precedent for cell‑based neurological therapies. Approval paves the way for commercialization and broader clinical deployment within Japan and could influence global regulatory attitudes toward pluripotent stem‑cell products for neurodegenerative conditions. The move is likely to accelerate investment and clinical programs in cell therapy for CNS disorders.